UY31973A - Derivados de indol macrocíclicos útiles como inhibidores del virus de la hepatitis c - Google Patents

Derivados de indol macrocíclicos útiles como inhibidores del virus de la hepatitis c

Info

Publication number
UY31973A
UY31973A UY0001031973A UY31973A UY31973A UY 31973 A UY31973 A UY 31973A UY 0001031973 A UY0001031973 A UY 0001031973A UY 31973 A UY31973 A UY 31973A UY 31973 A UY31973 A UY 31973A
Authority
UY
Uruguay
Prior art keywords
inhibitors
hepatitis
virus
indol derivatives
macrocyclic
Prior art date
Application number
UY0001031973A
Other languages
English (en)
Spanish (es)
Inventor
Vendeville Sandrine Marie Helene
Raboisson Pierre Jean-Mrie Bernard
Tse-I Lin
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of UY31973A publication Critical patent/UY31973A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
UY0001031973A 2008-07-08 2009-07-08 Derivados de indol macrocíclicos útiles como inhibidores del virus de la hepatitis c UY31973A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08159965 2008-07-08
EP08160254 2008-07-11
EP08161743 2008-08-04

Publications (1)

Publication Number Publication Date
UY31973A true UY31973A (es) 2010-01-29

Family

ID=40972916

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031973A UY31973A (es) 2008-07-08 2009-07-08 Derivados de indol macrocíclicos útiles como inhibidores del virus de la hepatitis c

Country Status (31)

Country Link
US (2) US8921355B2 (https=)
EP (1) EP2310396B1 (https=)
JP (2) JP5426671B2 (https=)
KR (1) KR101640374B1 (https=)
CN (1) CN102089314B (https=)
AP (1) AP2743A (https=)
AR (1) AR072726A1 (https=)
AU (1) AU2009267389B8 (https=)
BR (1) BRPI0915887B8 (https=)
CA (1) CA2729307C (https=)
CL (1) CL2011000032A1 (https=)
CO (1) CO6351793A2 (https=)
CR (1) CR20110076A (https=)
DK (1) DK2310396T3 (https=)
EA (1) EA019008B1 (https=)
EC (1) ECSP11010750A (https=)
ES (1) ES2651038T3 (https=)
HN (1) HN2011000072A (https=)
HR (1) HRP20171892T1 (https=)
HU (1) HUE035244T2 (https=)
IL (1) IL210086A (https=)
LT (1) LT2310396T (https=)
MX (1) MX2011000276A (https=)
NI (1) NI201100010A (https=)
NO (1) NO2310396T3 (https=)
NZ (2) NZ590073A (https=)
SI (1) SI2310396T1 (https=)
SV (1) SV2011003796A (https=)
TW (1) TWI454476B (https=)
UY (1) UY31973A (https=)
WO (1) WO2010003658A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2389994T3 (es) 2007-12-24 2012-11-05 Janssen R&D Ireland Indoles macrocíclicos como inhibidores del virus de la hepatitis C
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作c型肝炎病毒抑制劑之巨環吲哚衍生物
UA108211C2 (uk) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20130028865A1 (en) * 2010-04-13 2013-01-31 Medivir Ab Combination of a Macrocyclic Inhibitor of HCV, A Non-Nucleoside and a Nucleoside
CA2801517C (en) * 2010-06-24 2017-12-12 Janssen R&D Ireland Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7h-indolo-[2,1-.alpha.]-[2]-benzazepine-10-carboxylic acid
HUE035751T2 (hu) 2011-09-02 2018-08-28 Novartis Ag Gyulladásgátló szubsztituált ciklobuténdion vegyület kolinsó
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
US20150209366A1 (en) 2012-08-31 2015-07-30 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir
WO2014152275A1 (en) * 2013-03-14 2014-09-25 Concert Pharmaceuticals, Inc. Deuterium modified derivatives of the ns5b polymerase inhibitor tmc647055
US10450263B2 (en) 2017-02-10 2019-10-22 Southern Research Institute Benzo annulenes as antiviral agents
KR101974388B1 (ko) 2017-06-23 2019-05-02 (주)에니켐텍 알킬 디에틸렌 트리아민 유도체 및 이의 제조방법
WO2019133574A2 (en) * 2017-12-26 2019-07-04 Southern Research Institute Benzoannulene derivatives as antiviral agents
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
US12060148B2 (en) 2022-08-16 2024-08-13 Honeywell International Inc. Ground resonance detection and warning system and method
CN116425782A (zh) * 2023-03-22 2023-07-14 烟台盛凯伦化学科技有限公司 一种5-乙酰基-2-氟苯硼酸频哪醇酯的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US20050267836A1 (en) 1996-03-25 2005-12-01 Cfph, Llc Method and system for transacting with a trading application
CA2252465C (en) 1996-04-23 2007-07-03 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
DK0966465T3 (da) 1997-03-14 2003-10-20 Vertex Pharma Inhibitorer af IMPDH-enzymer
CA2367017C (en) 1999-03-19 2009-05-26 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
JP4778665B2 (ja) 2000-08-30 2011-09-21 パナソニック株式会社 プラズマディスプレイ表示装置の製造方法
PL1713822T3 (pl) 2004-01-30 2010-08-31 Medivir Ab Inhibitory proteazy serynowej HCV NS-3
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
AU2006286441A1 (en) 2005-09-02 2007-03-08 Janssen R&D Ireland Benzodiazepines as HCV inhibitors
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
GB0522881D0 (en) 2005-11-10 2005-12-21 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007092000A1 (en) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibitors of hcv replication
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521443B2 (en) 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2008043704A1 (en) 2006-10-10 2008-04-17 Medivir Ab Hcv nucleoside inhibitor
CA2672250C (en) 2006-12-20 2013-04-30 Ian Stansfield Antiviral indoles
JP2010533699A (ja) * 2007-07-17 2010-10-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー C型肝炎感染症の治療のための大環状インドール誘導体
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作c型肝炎病毒抑制劑之巨環吲哚衍生物
AR073603A1 (es) 2008-09-18 2010-11-17 Ortho Mcneil Janssen Pharm Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido
PL2401272T3 (pl) 2009-02-27 2017-06-30 Janssen Pharmaceuticals, Inc. Amorficzna sól makrocyklicznego inhibitora HCV
US20130028865A1 (en) 2010-04-13 2013-01-31 Medivir Ab Combination of a Macrocyclic Inhibitor of HCV, A Non-Nucleoside and a Nucleoside
CA2801517C (en) 2010-06-24 2017-12-12 Janssen R&D Ireland Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7h-indolo-[2,1-.alpha.]-[2]-benzazepine-10-carboxylic acid
US20150209366A1 (en) 2012-08-31 2015-07-30 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir

Also Published As

Publication number Publication date
NO2310396T3 (https=) 2018-02-03
SI2310396T1 (en) 2018-01-31
HUE035244T2 (hu) 2018-05-02
AU2009267389A8 (en) 2013-07-04
BRPI0915887B8 (pt) 2021-05-25
HN2011000072A (es) 2013-09-01
IL210086A0 (en) 2011-02-28
WO2010003658A1 (en) 2010-01-14
JP2011527299A (ja) 2011-10-27
MX2011000276A (es) 2011-03-02
JP5426671B2 (ja) 2014-02-26
JP5808370B2 (ja) 2015-11-10
CN102089314B (zh) 2014-07-23
IL210086A (en) 2014-05-28
US20110105473A1 (en) 2011-05-05
KR101640374B1 (ko) 2016-07-18
CR20110076A (es) 2011-11-10
TWI454476B (zh) 2014-10-01
BRPI0915887B1 (pt) 2020-02-18
AR072726A1 (es) 2010-09-15
JP2014028818A (ja) 2014-02-13
NZ590073A (en) 2012-11-30
EP2310396A1 (en) 2011-04-20
LT2310396T (lt) 2017-12-27
AU2009267389B2 (en) 2013-05-30
HK1155734A1 (en) 2012-05-25
EA019008B1 (ru) 2013-12-30
AP2743A (en) 2013-09-30
ECSP11010750A (es) 2011-08-31
CL2011000032A1 (es) 2011-07-15
US9427440B2 (en) 2016-08-30
HRP20171892T1 (hr) 2018-01-12
EP2310396B1 (en) 2017-09-06
US8921355B2 (en) 2014-12-30
AP2010005521A0 (en) 2010-12-31
EA201170153A1 (ru) 2011-08-30
TW201014865A (en) 2010-04-16
NI201100010A (es) 2011-09-07
DK2310396T3 (en) 2017-12-11
KR20110040889A (ko) 2011-04-20
NZ603343A (en) 2013-08-30
AU2009267389A1 (en) 2010-01-14
AU2009267389B8 (en) 2013-07-04
CO6351793A2 (es) 2011-12-20
CN102089314A (zh) 2011-06-08
US20140107101A1 (en) 2014-04-17
CA2729307A1 (en) 2010-01-14
SV2011003796A (es) 2011-04-08
ES2651038T3 (es) 2018-01-23
BRPI0915887A2 (pt) 2015-11-03
CA2729307C (en) 2017-08-29

Similar Documents

Publication Publication Date Title
UY31973A (es) Derivados de indol macrocíclicos útiles como inhibidores del virus de la hepatitis c
UY32759A (es) Inhibidores del virus de la hepatitis c
NI201500029A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b.
UY32793A (es) Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
UY31183A1 (es) Derivados de pirazinona y procesos para su preparación
CR20160237A (es) Derivados de la carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
MX2020010737A (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b.
UY35573A (es) Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
CO6561783A2 (es) Inhibidores del virus flaviviridae
NI201600115A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b.
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
CO6561788A2 (es) Inhibidores del virus de la hepatitis c
GT201400009A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk
CR20140089A (es) Nuevos derivados bicíclicos de dihidroquinolina-2-ona
DOP2014000133A (es) Triazolopiridinas sustituidas
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
ECSP15002066A (es) Inhibidores de virus de hepatitis c
UY32997A (es) Derivados bencimidazol-imidazol
ECSP12012104A (es) Inhibidores de virus flaviviridae
CO6321276A2 (es) Derivados de tiazol usados como inhibidores de pi3- cinasa
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
UY34066A (es) Inhibidores del virus de la hepatitis c